Abbott Laboratories (ABT) Net Income towards Common Stockholders (2009 - 2026)

Abbott Laboratories has reported Net Income towards Common Stockholders for 18 years, with the latest figure at $928.0 million in Q2 2026.

• Quarterly Net Income towards Common Stockholders fell 47.84% year-over-year to $928.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $5.4 billion (down 61.19% YoY) and the FY2025 annual result came in at $6.5 billion, down 51.32% from the prior year.
• Net Income towards Common Stockholders retreated to $928.0 million in Q2 2026 per ABT's latest filing, from $1.1 billion in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $9.2 billion in Q4 2024 and troughed at $928.0 million in Q2 2026.
• A 5-year average of $1.9 billion and a median of $1.4 billion in 2022 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders soared 478.98% in 2024, then sank 80.76% in 2025.
• Over 5 years, Net Income towards Common Stockholders stood at $1.0 billion in 2022, then soared by 54.31% to $1.6 billion in 2023, then jumped by 478.98% to $9.2 billion in 2024, then tumbled by 80.76% to $1.8 billion in 2025, then tumbled by 47.75% to $928.0 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $928.0 million, $1.1 billion, and $1.8 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.